SPY336.84+0.01 0.00%
DIA279.80+0.38 0.14%
IXIC11,019.30-23.20 -0.21%

Citigroup Maintains Buy on Coherus BioSciences, Raises Price Target to $31

Citigroup maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $27 to $31.

Benzinga · -

Citigroup maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $27 to $31.